TETRA Technologies, Inc.

TETRA Technologies, Inc. (TTI) Market Cap

TETRA Technologies, Inc. has a market capitalization of $1.13B.

Price: $7.70

0.08 (1.05%)

Market Cap: 1.13B

NYSE · time unavailable

CEO: Brady Murphy

Sector: Energy

Industry: Oil & Gas Equipment & Services

IPO Date: 1990-04-03

Website: https://onetetra.com

TETRA Technologies, Inc. (TTI) - Company Information

Market Cap: 1.13B|Sector: Energy

Company Profile

TETRA Technologies, Inc. (TTI) is a diversified enterprise that delivers a range of services to the oil and gas industry. The company organizes its operations into two primary divisions: Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products segment is responsible for the production and distribution of specialized chemical formulations, such as clear brine fluids, various additives, and complementary services. These products are vital for well drilling, completion, and workover procedures in the oil and gas sector, with a market presence spanning the United States, Latin America, Europe, Asia, the Middle East, and Africa. This division also trades in both liquid and dry calcium chloride products. The Water & Flowback Services segment offers comprehensive water management solutions designed for onshore oil and gas operators. Additionally, it provides services like frac flowback and production well testing, along with other related support. These services are delivered across oil and gas producing areas in the United States and Mexico, as well as in numerous basins throughout Latin America, Africa, Europe, and the Middle East. Founded in 1981, TETRA Technologies, Inc. is headquartered in The Woodlands, Texas.

Analyst Sentiment

92%
Strong Buy

From 4 Active Polls

1Y Forecast: $12.00

▲ +55.8% Potential Upside

Consensus Target Metrics

Low Bound

$10

Median

$12

High Bound

$14

Average

$12

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$12.00
▲ +55.84% Upside
Low Target
$10.00
30% Risk
Median Target
$12.00
56% Mid
High Target
$14.00
82% Max
Consensus
Buy
18 / 31 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,1261,1461,254767447445472408440
Enterprise Value ($M)1,3151,3351,472915596618656573611
Price to Earnings Ratio (P/E)113.4034.41-21.3046.229.8927.451.15-33.9914.39
Price/Earnings-to-Growth Ratio (PEG)5.270.931.631.04
Price to Sales Ratio (P/S)1.797.338.555.012.572.833.512.882.56
Price to Book Ratio (P/B)3.613.994.422.591.541.631.852.602.84
Price to Free Cash Flow Ratio (P/FCF)419.27-37.12306.911223.5415.51-31.72-51.0077.0046.59
Enterprise Value to Sales (EV/Sales)8.5410.045.973.423.944.884.053.55
Enterprise Value to EBITDA (EV/EBITDA)15.2955.61207.2741.4918.1532.6129.8526.6522.28
Debt to Equity Ratio2.200.780.930.720.750.790.871.371.38

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 TETRA TECHNOLOGIES INC (TTI) — Investment Overview

🧩 Business Model Overview

Tetra Technologies operates in the upstream oil & gas value chain by supplying engineered technologies and services used to manage and optimize production operations. The business links the customer’s production needs (well completion, intervention, and fluid handling) to specialized process and product solutions—particularly around production fluids and water management.

In practical terms, TTI monetizes its capability by tailoring chemistry, process equipment, and operational support to field requirements, then delivering solutions that fit into customers’ operating workflows (from sourcing and handling fluids to treatment and reuse/disposal decisions). This “in-field integration” tends to create stickiness because solutions must meet performance and safety standards and be compatible with existing well designs and field logistics.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by (1) sales of technology/process solutions and related equipment, and (2) service activity tied to customer well and production operations. Monetisation typically blends transactional components (fluid/service jobs and equipment deployments) with elements that resemble recurring economics when customers consistently require the same treatment approach across multiple wells or pads.

Margin drivers are usually a function of:

  • Field execution and utilization: fixed and semi-fixed cost absorption tied to service volumes.
  • Value-added mix: higher-margin process/technology offerings versus more commoditized chemical or service work.
  • Pricing discipline and product quality: chemistry and process performance can reduce non-productive time and operational risk, supporting better unit economics.
  • Logistics efficiency: proximity of operations to customer activity reduces handling and deployment costs.

🧠 Competitive Advantages & Market Positioning

TTI’s competitive position is best characterized as a specialty technology and field-qualification moat rather than scale-based cost leadership. Competitors can offer similar categories of products, but TTI’s advantage is the ability to match process solutions to reservoir/production conditions and deliver repeatable outcomes after customer qualification.

Moat mechanics (hard-to-replace elements):

  • Switching Costs (Field Qualification): Changing suppliers can require retesting, operational adjustments, and process validation, which raises friction and cost for operators.
  • Operational Intangibles: Process know-how, formulation expertise, and field execution experience create an advantage that is not easily replicated by new entrants.
  • Geographic/Logistical Advantage: Service delivery depends on deployment readiness and proximity to active basins, which can lower total delivered cost and improve responsiveness.

Competitive Benchmarking:

  • Halliburton and Schlumberger (and similarly Baker Hughes) offer broad integrated well services and fluids capabilities across many product lines.
  • Regional specialty providers (including basin-focused frac/well-service and water-treatment operators such as Calfrac-type service models) compete on localized execution and specialized offerings.

TTI’s differentiating focus is narrower and more technology/process-oriented, emphasizing engineered solutions for production-fluid and operational challenges rather than competing head-to-head with the service majors on breadth alone.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, the TAM for TTI’s end-markets is supported by secular operational needs in upstream production:

  • Produced water and fluid management intensity: As field maturity increases, more complex water-handling and treatment requirements tend to persist across cycles.
  • Operational efficiency and risk reduction: Operators continue to prioritize solutions that support throughput, reliability, and compliance—areas where qualified technology partners can embed.
  • Repeatable deployments across well programs: Once a process approach is proven, multi-well pad development and field expansion can create a durable demand base for the same supplier.
  • Basins with long production lives: Durable activity profiles in major U.S. basins can support steady requirements for interventions and production-fluid services, even when activity levels fluctuate.

⚠ Risk Factors to Monitor

  • Capital intensity and asset utilization: Execution depends on keeping assets and field teams deployed efficiently; downturns can compress returns.
  • Customer budget cyclicality: Upstream operators control spend through commodity-driven capital programs, affecting service volumes and contract terms.
  • Competitive pressure on pricing: Major integrators and basin specialists can contest pricing when demand weakens.
  • Technology performance risk: Process solutions require consistent performance under varying reservoir and operating conditions; underperformance can lead to customer churn.
  • Regulatory and compliance costs: Produced water handling and disposal/regulatory requirements can change, impacting cost structure and permitting timelines.

📊 Valuation & Market View

The market typically values oilfield services and specialty energy technology providers using EV/EBITDA or enterprise-value-to-cash-flow frameworks, with expectations shaped by (1) the durability of order flow across commodity cycles, (2) margin quality and mix, and (3) working-capital discipline.

Key valuation drivers that tend to move sentiment include:

  • Service utilization and margin recovery: whether revenue translates into sustainable operating profit through cycles.
  • Mix shift toward higher-value technology/process offerings: improving gross margin and reducing volatility.
  • Contract structure and cash conversion: terms that support predictability and minimize cash tied up in receivables/inventory.

🔍 Investment Takeaway

Tetra Technologies offers exposure to upstream production-fluid and process requirements through specialized technology and field-qualified service delivery. The investment case rests on switching costs from qualification/operational integration and technology-driven execution advantages, with growth supported by structurally rising complexity in produced-water management and operational efficiency needs. The primary underwriting risk is cyclicality in upstream capital spending and the ability to sustain margins through utilization and mix discipline.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for TTI.

globenewswire.com2026-07-30

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

zacks.com2026-07-28

Tetra Technologies (TTI) to Report Q2 Results: What to Know Ahead of the Release

Tetra Technologies (TTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

prnewswire.com2026-07-13

TETRA TECHNOLOGIES, INC. ANNOUNCES DATE FOR SECOND QUARTER 2026 EARNINGS CONFERENCE CALL

SPRING, Texas, July 13, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE:TTI) will release Second Quarter 2026 results after the market closes on August 3, 2026 and will host a conference call to discuss the results and outlook on August 4, 2026, at 10:30am ET. CLICK HERE to pre-register and obtain your dial in number and passcode.

newsfilecorp.com2026-07-13

Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome

San Diego, California--(Newsfile Corp. - July 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing novel sulfur-based thiol therapies for rare pediatric, metabolic and mitochondrial disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth through 18 years of age.

seekingalpha.com2026-07-07

Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript

Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript

globenewswire.com2026-07-07

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding Company to host investor webcast today, July 7 th , at 8:30am ET HOUSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound's mechanism of action.

zacks.com2026-06-29

Tetra Technologies (TTI) Soars 6.6%: Is Further Upside Left in the Stock?

Tetra Technologies (TTI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

prnewswire.com2026-06-29

TETRA TECHNOLOGIES INTRODUCES TETRA NEPTUNE Z-LITE DEEPWATER COMPLETIONS FLUID

Using Neptune Chemistry to Achieve Required Density With Lower Zinc Content; Awarded Three-Well 20k psi Deepwater Project in the Gulf of America With Estimated Start in 2026 SPRING, Texas, June 29, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) today announced the introduction of TETRA Neptune Z-Lite, a high-density completion fluid designed for deepwater and high-pressure well applications. The fluid system uses our patented Neptune fluid chemistry and expands the Company's completion fluids portfolio by offering up to 60% lower zinc-ion concentration than conventional zinc-based fluids while maintaining required density performance.

seekingalpha.com2026-06-24

TETRA Technologies, Inc. (TTI) Presents at J.P. Morgan Natural Resources Conference 2026 Transcript

TETRA Technologies, Inc. (TTI) Presents at J.P. Morgan Natural Resources Conference 2026 Transcript

newsfilecorp.com2026-06-17

Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

San Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr. Aharon is a Co-Founder and Portfolio Manager at Rosalind Advisors, Inc., a Toronto-based life sciences institutional investor.

zacks.com2026-06-16

Can Viavi's New TETRA Testing Upgrade Strengthen Its Growth Story?

VIAV's new TETRA testing upgrade for the CX300 aims to speed deployments, cut costs, and reinforce its position in mission-critical radio testing.

prnewswire.com2026-06-15

VIAVI Launches TETRA MS Base Station Simulator Option for CX300 to Simplify and Speed Mission-Critical Radio Testing

Allows full testing of TETRA MS radios, including transmitter parametric measurements, call processing and BER/MER loopback without the need to place radios in T1 test mode CHANDLER, Ariz., June 15, 2026 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) has announced a TETRA MS radio base station simulator option for its field-portable CX300 communications service monitor.

fool.com2026-06-13

Is TETRA Technologies a Buy After An Insider Bought 22,000 Shares?

Hallead acquired 22,000 shares on June 9, 2026, at a weighted average price of $9.86 per share, representing a transaction value of ~$217,000. This purchase increased his direct ownership by 14.79%, bringing his direct holdings to 170,764 shares after the transaction.

newsfilecorp.com2026-06-03

Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million

San Diego, California--(Newsfile Corp. - June 3, 2026) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing a next-generation cysteamine-based therapy for rare diseases, is pleased to announce that, further to its news releases of May 11 and June 1, 2026, it has completed an oversubscribed non-brokered private placement (the "Offering") through the issuance of 18,143,700 common shares (the "Offered Shares") at a price of C$0.50 per Offered Share for gross proceeds of C$9,071,850. All securities issued in connection with the Offering are subject to a four-month plus one day hold period ending October 2, 2026.

gurufocus.com2026-06-03

TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock

TETRA Technologies, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire SPRING, Texas, June 2,

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"TTI reported Q1’26 revenue of $156.3M and net income of $8.32M (EPS $0.0619). On a YoY basis, revenue rose to $156.3M from $157.1M in Q1’25 (-0.6%), while net income increased from $4.05M to $8.32M (+105.5%). QoQ, revenue increased from $146.7M in Q4’25 (+6.6%), and net income swung from -$16.5M to +$8.32M (turnaround). Profitability improved: gross margin expanded to 24.5% in Q1’26 from 21.8% in Q4’25, and net margin turned positive to 5.3% versus -11.2% in Q4’25 (though still below the stronger Q2’25/Q3’25 operating environment). Cash flow weakened in the quarter—operating cash flow was -$11.9M and free cash flow was -$30.9M, driven by working-capital and non-cash items—contrasting with positive Q4’25 operating cash flow (+$31.7M). Balance sheet resilience is mixed: reported equity is $286.9M, but total debt rose on the quarter (net debt ~+$48.5M vs. much higher in prior quarters per the dataset), and liquidity metrics cannot be reliably assessed due to missing/zero cash and asset line items in Q1’26 balance. On shareholder returns, the stock shows strong momentum: +267% over 1 year, with no dividend (0% yield) and no buybacks/dividends disclosed in Q1’26 cash flow. Total return appears dominated by capital appreciation."

Revenue Growth

Neutral

QoQ revenue rose +6.6% ($146.7M to $156.3M) while YoY was slightly down -0.6% ($157.1M to $156.3M), indicating flat-to-slightly weak top-line momentum.

Profitability

Strong

Net income improved sharply YoY (+105.5%) and QoQ (from -$16.5M to +$8.3M). Gross margin expanded to 24.5% in Q1’26 from 21.8% in Q4’25, and net margin turned positive to 5.3%.

Cash Flow Quality

Fair

Q1’26 operating cash flow was -$11.9M and free cash flow was -$30.9M, a deterioration versus Q4’25 (OCF +$31.7M; FCF +$4.1M). Earnings improved, but cash conversion worsened this quarter.

Leverage & Balance Sheet

Neutral

Equity is $286.9M in Q1’26, but the balance sheet dataset shows zeros for many asset/cash line items in Q1’26, limiting confidence. Debt levels appear to have shifted materially; resilience is not fully comparable quarter-to-quarter in the provided data.

Shareholder Returns

Strong

Total return is strongly supported by price momentum: +267.1% over 1 year. Dividend yield is 0%, and Q1’26 cash flow shows no repurchases/dividends, so performance is primarily capital appreciation.

Analyst Sentiment & Valuation

Neutral

Price is $8.81 versus consensus target $12.25 (implied upside ~39%). Valuation multiples from the dataset are inconsistent across quarters, but sentiment appears modestly bullish given targets.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

TTI delivered an unusually strong Q1, driven by resilience across completion fluids, production testing automation, and record industrial chemicals performance, despite a quarter without Neptune follow-through in-line with 2026 expectations. Management repeatedly tied upside to (1) offshore deepwater pull-forward logic, (2) higher-density completion fluid demand from hotter, deeper Gulf of America wells, and (3) international scaling of automated SandStorm Production Testing technology—now with international PT revenue surpassing 50% of the subsegment. Financially, results were cited as 10-year highs for revenue and adjusted EBITDA even after normalizing for prior-year Neptune benefits, and Water & Flowback margin expansion occurred despite U.S. frac fleet declines, primarily from automation and cost actions. Outlook remains constructive with maintained 2026 guidance (single-digit revenue growth; Completion Fluid margins 25%–30%; Water mid-teens). Key execution focus areas are OASIS engineering-to-commercial conversion and continued on-time construction toward early 2028 bromine production, supported by cash generation and reinvestment.

AI IconGrowth Catalysts

  • Industrial Chemicals: record-setting Q1 revenue up 15% YoY and 13% QoQ, with Completion Fluids & Products Industrial Chemicals driving over 50% of segment revenue for the first time since 2021
  • Completion Fluids: higher-pressure gas plays in South Texas and Western Haynesville supporting Gulf Coast LNG, driving higher volumes of higher-value completion fluids
  • Completion Fluids: disposal well pore space in West Texas contributing to higher density fluids for well workovers
  • Gulf of America fluids: trend toward deeper, hotter wells evidenced by very strong Q1 revenues for highest density Zinc Bromide Completion Fluid
  • Production Testing: SandStorm automation gaining market share across unconventional land operations in the U.S., Argentina, and the Middle East; international PT revenue over 50% for the first time in 10 years

Business Development

  • OASIS TDS produced-water desalination: multiple parallel engineering studies (for both smaller-sized plant and 100,000-barrel-per-day plant) to move into more commercial discussions before end of Q2
  • Magnesium JV: joint venture with Magrathea Metals (Arkansas Magnesium) advancing domestic magnesium metal production; first formal Board meeting; engineering studies for a first-of-a-kind demonstration plant planned for co-location at the Evergreen Bromine site in Arkansas
  • Lithium resource economics: Evergreen brine unit (Southwest Arkansas) where TETRA owns 65% of brine mineral rights and ExxonMobil owns 35%; TETRA’s upstream wells contain lithium, magnesium, and bromine minerals in the same brine system
  • Battery electrolyte supply planning: long-term supply agreement plus secured additional third-party bromine supply to meet EOS requirements and ramp plans (EOS eight GWh cited publicly)

AI IconFinancial Highlights

  • Reported Q1 2026 strength: excluding Gulf of America Neptune benefit from Q1 last year, revenue $156 million and adjusted EBITDA $26 million were 10-year highs
  • Segment highlights: Completion Fluids & Products revenue $92 million (+10% vs Q4 2025) and adjusted EBITDA $26 million (+12%); YoY revenue down 1% and adjusted EBITDA down 23% due to absence of high-impact Neptune projects in first half 2025
  • Water & Flowback: revenue $65 million (+3% QoQ, +1% YoY) while U.S. frac fleets down 24% YoY; adjusted EBITDA $9 million (+20% sequential, +9% YoY) driven by cost reduction and market penetration of higher-margin automation technology
  • Industrial Chemicals: revenue up 15% YoY and 13% QoQ; Industrial Chemicals accounted for over 50% of total first quarter segment revenue (first time since 2021)
  • Guidance maintained for 2026: single-digit revenue growth vs 2025; Completion Fluid margins between 25% and 30%; Water & Flowback in the mid-teens
  • Tax/tariff and bps: no explicit bps margin movements or tax/tariff impacts stated in provided transcript

AI IconCapital Funding

  • Balance sheet at quarter end: $36 million cash; $182 million total debt; net leverage ratio 1.5x
  • Cash flow: cash used in operating activities $12 million; total CapEx $19 million including $8.4 million for Arkansas bromine project
  • Free cash flow: total adjusted free cash flow use of $32 million; base business adjusted free cash flow use of $23.5 million
  • Uses of cash: higher incentive compensation tied to strong 2025 results; build in AR balance and seasonal Europe inventory build monetized in Q2
  • Funding plan: expect to generate positive base business free cash flow in 2026; cash reinvested into Arkansas bromine plant; intends to finance remaining 2027/into 2028 bromine project primarily from free cash flow, with “very good options” if additional capital is required
  • Buybacks: no buyback authorization or repurchase amount disclosed in the transcript

AI IconStrategy & Ops

  • Water & Flowback profitability improvement tied to cost reduction and continued market penetration of higher-margin automation (automation technology highlighted as key driver)
  • Production Testing expansion strategy: international growth successful; automation SandStorm technology gaining market share and enabling international scaling
  • Supply chain resilience: chemical manufacturing plants located in U.S. and Europe; elemental bromine sourced from Arkansas; Middle East conflict expected not to materially impact operations because production is not Middle East-based
  • OASIS ramp: engineering studies (multiple parallel tracks) to finalize OpEx/CapEx inputs and demonstrate cost competitiveness vs disposal alternatives; aim to enter more commercial discussions before end of Q2
  • Arkansas bromine project milestones: Phase 1 completed (titanium bromine tower erected); Phase 2 underway; more on-site construction activity expected in 2027 and 2028; project still projected for early 2028 production
  • Electrolyte strategy: maintain readiness to supply PureFlow Zinc Bromide inputs for EOS ramp via long-term supply plus additional third-party bromine

AI IconMarket Outlook

  • Geopolitical impact: Middle East historically ~5% of revenue; management expects activity slowdowns/delays to be offset by other regions (U.S., Europe, Latin America); some Q2 2026 Middle East completion fluid sales could be delayed
  • Oil & gas price sensitivity: at current oil prices, offshore projects may be pulled forward; unconventional activity in U.S. expected to respond over time; confidence reaffirmed while maintaining prior 2026 guidance
  • Capital planning: expects positive base business free cash flow in 2026 with reinvestment into Arkansas bromine plant
  • OASIS timeline: management expects to get into more commercial discussions with customers before end of Q2 (engineering studies to complete before long-term contracts)
  • Production Testing: international expansion trend expected to persist given automation exportability and regional energy-security demand

AI IconRisks & Headwinds

  • Middle East conflict: offshore activity in Middle East slowed; logistics delays and higher costs; “some” Q2 2026 completion fluid sales in Middle East could be delayed (exposure described as relatively small vs total business)
  • Execution risk: OASIS requires engineering study completion before long-term contracts; management explicitly stated there is still “a ways to go”
  • Neptune timing uncertainty: no Neptune projects expected in 2026 guidance; pipeline probabilities for Neptune appear to be increasing for next year, creating timing variability
  • U.S. frac softness: U.S. frac fleets down 24% YoY during quarter; profitability offset relied on cost reduction and automation penetration rather than volume recovery alone
  • Electrolyte supply/technology risk: no forecasting comment on EOS manufacturing hiccups beyond confirming secured third-party bromine supply (EOS hiccups cited publicly; management declined specifics)

Q&A: Analyst Interest

  • OASIS TDS commercial trajectory: Management described multiple parallel engineering studies (smaller-sized plant and 100,000 bpd) and said enough OpEx/CapEx inputs should be socialized with customers before end of Q2. They emphasized studies must finish before long-term contracts and declined customer names.
  • Deepwater/Neptune timing: Analysts asked whether there are indications of Neptune-related demand beyond 2026. Management cited stronger deepwater outlook strengthened by Middle East churn, described hotter, more challenging wells, confirmed growing Neptune pipeline, and said probabilities for next year are increasing while 2026 still may not include Neptune.
  • Arkansas bromine project construction and funding needs: Management confirmed Phase 1 completion (titanium tower erected) and said much of the remaining on-site work—pipelines, pretreatment, tower-related construction—runs through 2027 and 2028. They indicated 2027 cash flows and 2026 positive base FCF should fund most needs, using free cash flow with contingency financing options.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the TTI Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for TTI.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (TTI)

© 2026 Stock Market Info — TETRA Technologies, Inc. (TTI) Financial Profile